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The development of oxytocic drugs in the management of
postpartum haemorrhage
Thomas F Baskett
Throughout history obstetric haemorrhage has
been a major cause ofmaternal mortality in both
developedanddevelopingcountries.1'2Theoldest
work in obstetrics and gynaecology, published
towardtheendofthefirstcenturyAD,isattributed
to Soranus ofEphesus, who broughttogether the
knowledge of obstetrics, gynaecology and
paediatrics ofthatera.3 Soranus gives no account
of oxytocic medications but does give some
sensible advice on the general management of
hyopvolaemic shockassociated with postpartum
haemorrhage, advising that the woman should
'lie down in a relatively small, dark and
moderately cool roomupon ahard bed ... raised
a little at the foot'. He also described what could
be regarded as the forerunner of the Medical
AntishockTrousers(MAST): 'andtheextremities
should be gripped tightly and bandaged, for the
compression resulting from this squeezing is
transmitted all the way to the affected part'.'
Uterine atony accounts for80-85% ofall cases of
primary postpartum haemorrhage (PPH). Once
theplacentaseparatesfromtheuterinewallinthe
third stage of labour, it leaves a very vascular
placentalbedwithtornbloodvessels. Theuterine
musculature, through which the blood vessels
that supply the placental bed pass, is arranged in
an interlocking criss-cross fashion, such that
contraction of these muscle fibres effectively
constricts the blood vessels.4 This anatomical
and physiological mechanism of haemostasis is
sometimes known as the 'living ligatures' or
'physiological sutures' of the uterus. Indeed, it
has been known for centuries that contraction of
the uterus was necessary to stop bleeding after
separation and delivery of the placenta. In the
Ebers Papyrus (circa 1500 BC), drugs used to
promote uterine contractions included hemp in
honey, celery in milk, juniper berries and fly
excrement.5 Details of the method ofcollection,
dose, and route ofadministration ofthe latter are
not given. Dioscorides, a physician who lived in
the 1st century AD, studied and documented the
medicinal use of plants in his major work De
Materia Medica, which formed the basis of
therapeutic practice of Western medicine until
the 17th century. He claimed oxytocic properties
forthe cyclamen plant and said that ifthe root of
the cyclamen plant was 'tyed about her it doth
hasten thebirthe'.6 John Gerard, Royal Herbalist
and Curator ofthe College ofPhysicians Physic
Garden in London in the 17th century, attributed
similar oxytocic properties to the plant chervil.7
ERGOT AND ITS ALKALOIDS
The first effective oxytocic drug was ergot,
derived fromthe fungus Clavicepspurpurea that
grewontheears ofcerealgrains, particularlyrye.
The disease ergotism was caused by eating rye
bread contaminated with the fungus ergot.
Epidemics of ergotism have occurred for more
than 1000 years and were caused by wet seasons
leading to damp cereal crops which favoured
growth ofthe fungus. These epidemics tended to
occur in areas of France, Russia and Southern
Germany where the cereal rye was grown
extensively. The usual manifestation was
gangrene of the peripheries associated with
progressive vasospasm. The more rare type of
ergotism mainly involved the central nervous
system andwas known as the convulsive variety.
During epidemics of ergotism it was observed
that pregnant women would miscarry and
midwives therefore deduced that ergot caused
uterine contractions and began using it for
prolonged labour with ineffective uterine
contractions8' 9 It was administered by grinding
upthegrainsofthefungus andadministeringitin
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powder form. It came to be called pulvis ad
partum (the powder of birth). It was probably
used first and most extensively by midwives in
Germany, and the first written reference is by
Adam Lonicer in his Krauterbuch or Book of
Herbs in 1582.10 In 1787 Paulitsky noted the
increasinguseofergotinlabour, claiming: ... all
are reassured that it makes labour quicker and
more powerful than any other remedies'. 1
Theuseofergotinobstetrics increasedfollowing
the 1808 publication ofaletterbyJohn Stearns in
theMedicalRespository ofNew York.12Working
inrural New York, Stearns apparently learned of
ergot from 'an ignorant Scottish midwife'. In his
letter, written to a colleague in 1807, he outlined
the advantages of ergot to 'expedite lingering
parturition'.Heobservedthatthepainsstimulated
by ergot were 'peculiarly forcing'. He also noted
that the response to ergot could be very rapid,
claiming "since I have adopted the use of this
powder I have seldom found a case that detained
me more than three hours".'2Unfortunately, the
response to ergot was unpredictable and as a
result tetanic uterine contractions led to fetal
asphyxia, stillbirth and uterine rupture. Stearns
himself was later to emphasize the 'necessity of
extreme caution'.'3 The misuse of ergot and its
complications weresummarizedbyDavidHosack
who feltthe name shouldbe changed topulvis ad
mortem.'4 Gradually, due to the influence of
Hosack, Stearns and Oliver Prescott of
Massachusetts,"5theuseofergotwasemphasized
forpostpartumhaemorrhageandnotgivenbefore
the birth of the infant.
By the late 19th and early 20th century analysis
ofthealkaloidscontainedinergotwasunderway.16
The alkaloids ergotoxine 7 and ergotamine'8 had
oxytocicpropertiesandbecamethestandarddrugs
for this purpose. In 1932, Chassar Moir, then a
registrar in obstetrics at the University College
Hospital in London, found that the powerful
oxytociceffectwaspresentintheaqueous extract
of ergot.'9 Working with the research chemist
Harold Dudley, he studied dozens of chemical
fractions ofthe aqueous extract of ergot, testing
the oxytocic properties on postpartum patients
with intrauterine pressure measurements. After
three years, the pure crystalline substance,
ergometrine, was discovered.20 Almost
simultaneouslyfromthreeothercentres: Davisin
Chicago,2' Thompson in Baltimore22 and Stoll in
Switzerland23theisolationofanewwater-soluble
extractofergotwas announced. All ofthese were
ultimately showntobeidentical. Thepreparation
was called ergometrine in the UK and
Commonwealth countries, ergonovine in the
United States and ergobasine in Switzerland. In
1940, Edward Davis of Chicago was the first to
advocate active management ofthe third stage of
labour with 0.2 mg ergometrine given
intravenously with delivery of the fetal head.24
Davis and his colleague, Melbourne Boynton,
later reported 2000 cases treated in this fashion
andfoundareductioninpostpartumhaemorrhage
with no increased risk of retained placenta.25
Shortly afterergometrine was discovered a study
of 500 consecutive cases was undertaken at the
University College Hospital in London but not
reporteduntil 1947.26Anotherobservational study
fromManchesteralsoshowedthattheroutineuse
of ergometrine reduced the blood loss and need
for blood transfusion.27 The first comparative
study was carried out by Dorothy Daley from
Carlshalton and published in 1951.28 She found
that those patients receiving active management
withergometrinehadanapproximately40%lower
risk of postpartum haemorrhage. Interestingly,
this level of risk reduction for PPH was later
substantiated in randomized controlled trials.29
POSTERIOR PITUITARY EXTRACT
Physiological experiments by Henry Dale on
posterior pituitary extract showed that it had an
oxytocic effect.30 Dale gave some samples to the
obstetricianWilliamBlairBell(laterthefounding
president of the Royal College of Obstetricians
and Gynaecologists) who published its use in
clinicalpractice in 1909.1' He noted the dramatic
oxytocic effect in cases of atonic postpartum
haemorrhage. Posteriorpituitaryextractwasused
inobstetricsand,unfortunately,thesamemistakes
made with ergot 100 years before were repeated
vis-a-visexcessiveuterineactivity,fetalasphyxia
and uterine rupture. In 1928, Kamm and
colleagues, working in the Parke-Davis
laboratories in the United States, showed that
pituitary extractcouldbe splitinto twofractions,
one oxytocic (Pitocin) and the other vasopressin
(Pitressin).32 However, pitocin didhave acertain
amount ofvasopressin so, while it was saferthan
the original extract, it was not devoid of
vasopressor side effects.
A major advance was the work of Du Vigneaud
and his colleagues at Cornell University in New
Yorkwho identified thechemical structureofthe
activeprinciples ofoxytocinandvasopressin; for
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were in widespread use both for the prevention
andthemanagementofpostpartumhaemorrhage.
Bythe 1980s severalrandomisedcontrolledtrials
and subsequent meta analysis confirmed the
effectiveness of active management of the third
stageoflabourinreducingbloodloss,postpartum
haemorrhage, the need for therapeutic doses of
oxytocic drugs and the need for blood
transfusion.29'34Active management of the third
stage may also reduce the risk of acute uterine





Prostaglandins are a ubiquitous group of
substances produced in virtually all tissues. The
New York gynaecologist, Raphael Kurzok,
noticedthatduring artificial insemination semen
was often actively expelled from the uterus. He
therefore carried out experiments with strips of
uterine muscle anddemonstratedits contractility
inresponse to semen.36This workwas confirmed
by Goldblatt in England 37 and by von Euler38 at
theKarolinskaInstituteinStockholm. VonEuler,
believing the active substance to come from the
prostate gland, named it 'prostaglandin'.39 In the
1960s Sune Bergstrom and his colleagues in
Stockholm identified the individual members of
the prostaglandin group.40 Prostaglandin F2 a
was most extensively investigated and it was
foundthatbyincorporating amethyl group atthe
15-position its half life was extended. The first
analogue of PGF2ca was 15-methyl PGF2a
(carboprost).41 This was subsequently shown to
be effective in many cases of uterine atony that
wereunresponsivetooxytocinandergometrine.42
The use of prostaglandins to prevent and treat
postpartum haemorrhage due to uterine atony
was first suggested by Bygdeman and his
colleagues in 1968.43 Shigeo Takagi of Tokoyo
wasthefirsttousedirectintramyometrialinjection
of prostaglandin F2a for atonic postpartum
haemorrhage.44 Corsonetal 45andHayashi eta146
found that 15-methyl PGF2a was better with
fewergastrointestinalandvasopressorsideeffects
but with strong uterotonic activity.
The need for a safe, cheap and widely available
oxytocic for the prevention and management of
uterine atony led to the investigation of another
prostaglandin, the PGE1 analogue misoprostol,
for this purpose.47 The first use of this agent for
the prevention ofPPH was by El-Rafaey and his
colleagues at the University College Hospital,
London where Chassar Moir had carried out his
classic work on ergometrine 75 years before.48
Others have used misoprostol by the rectal route
good effect.49'50
Thus, the modern era of oxytocic drug
development started with the discovery of
ergometrine in 1935, and has occurred in
approximately 20 year epochs over the last 70
years (Table). Oxytocin and ergometrine, or a
combination thereof, remain the standard
oxytocics for the prevention and treatment of
PPH. The more expensive 15-methyl PGF2a is a
valuable alternative in cases unresponsive to
oxytocin and/or ergometrine. Misoprostol does
not require injection for its administration and is
the cheapest, most stable, and easily stored ofall
oxytocic drugs. As such it has the most potential
for widespread use and benefit in the developing
world, where99% ofmaternal deaths duetoPPH
occur. However, the efficacy, dose, and route of
administration (oral, sublingual, rectal) have yet
to be delineated.5'
TABLE
Evolution ofOxytocic Drugsfor PPH
Year Author Drug
-1500 BC Ebers papyrus5 celery, hemp, juniper,
fly excrement
-1000 AD Dioscorides 6 cyclamen
1582 Lonicer 10 ergot
1787 Paulitsky 1 ergot
1808/1822 Stearns 12'13 ergot
1813 Prescott '5 ergot
1906 Barger 17 ergotoxine
1909 Blair Bell 31 pituitary extract





1950s Du Vigneaud3 oxytocin
1970s Bergstrom,40 15-methyl PGF2a
Karim 41 (carboprost)
1990s El-Rafaey 48 misporostol
and others 49,50
C The Ulster Medical Society, 2004.
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